Study: Crystal structures of fluorescent proteins determined

Researchers have determined the crystal structures of red fluorescent protein TagRFP and its derivative, the blue fluorescent protein mTagBFP and have proposed a chemical mechanism by which the red color in fluorescent proteins is formed from blue, according to study results published April 23 in Chemistry & Biology.

Vladislav V. Verkhusha, PhD, associate professor of anatomy and structural biology at Albert Einstein College of Medicine in Bronx, N.Y., demonstrated that mTagBFP was a new type of the chromophore, N-[(5-hydroxy-1H-imidazole-2-yl) methylidene] acetamide.

The researchers also proposed a chemical mechanism in which the red-like chromophore is formed via the mTagBFP-like blue intermediate.

“Knowing the molecular structures of the chromophores--the part of fluorescent protein molecules that gives them their color--we can now do hypothesis-based designing of new probes, instead of relying on random mutations,” said Verkhusha.

Researchers can now follow only two or three proteins at a time. “To understand many cellular functions, you would like to follow dozens of different proteins, so the more colors we can develop, the better,” said study co-author Steven C. Almo, PhD, professor of biochemistry and of physiology and biophysics at Albert Einstein.

Using this new information, Verkhusha’s laboratory has already designed a variety of new fluorescent proteins that can glow in colors ranging from blue to far-red and recently viewed individual breast cancer cells for several days at a time to study metastasis.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.